%0 Journal Article
%T Effectiveness and Safety of 9-Month Treatment Regimen for Multidrug-Resistant Tuberculosis in the Philippines
%A Vivian S. Lofranco
%A Vincent M. Balanag Jr
%A Lawrence O. Raymond
%A Noel G. Macalalad
%A Alex Golubkov
%A Mary Rosary T. Santiago
%A Anna Marie Celina G. Garfin
%J Journal of Tuberculosis Research
%P 75-86
%@ 2329-8448
%D 2022
%I Scientific Research Publishing
%R 10.4236/jtr.2022.102006
%X <span><span style=\"font-family:;\" \"=\"\"><span style=\"font-family:Verdana;\"><b></b></span><b><b><span style=\"font-family:Verdana;\">Background</span></b></b></span></span><b><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">:</span></span></span></b><span><span><span style=\"font-family:;\" \"=\"\"><span style=\"font-family:Verdana;\"> The Philippines has a burden of drug-resistant</span><b> </b><span style=\"font-family:Verdana;\">tuberculosis
(DR-TB). One of the key challenges in the programmatic management of DR-TB
(PMDT) is the high rate of loss to follow-up (38% in the 2010 cohort). An
urgent need for a shorter, more tolerable, less expensive treatment regimen
exists. The aim of the operational study is to determine the efficacy and
safety of the short treatment regimen among drug resistant TB.</span></span></span></span><span><span><span style=\"font-family:;\" \"=\"\"> </span></span></span><span><span><span style=\"font-family:;\" \"=\"\"><span style=\"font-family:Verdana;\"><b></b></span><b><b><span style=\"font-family:Verdana;\">Methods</span></b><span style=\"font-family:Verdana;\">:</span></b></span></span></span><b><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"></span></span></span></b><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"> This is a prospective single-arm cohort study evaluating the effectiveness
and safety of a shorter 9</span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"> - </span></span></span><span><span><span style=\"font-family:;\" \"=\"\"><span style=\"font-family:Verdana;\">11-month treatment regimen (9MTR) for rifampicin-resistant/multi-drug
resistant TB (RR/MDR-TB) in 10 PMDT facilities. A</span><span><span style=\"font-family:Verdana;\">ll eligible consenting adult patients with rifampicin-resistant TB</span><b> </b><span style=\"font-family:Verdana;\">were</span></span><span style=\"font-family:Verdana;\"> enrolled and received the standardized 9-month treatment regimen (9MTR),
including injectables, with a follow-up after 12 months of treatment
completion. <b></b></span><b><b><span style=\"font-family:Verdana;\">Results</span></b><span style=\"font-family:Verdana;\">:</span></b></span></span></span><b><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"></span></span></span></b><span
%K MDR-TB
%K Short Treatment Regimen
%K Treatment Outcomes
%K Prospective Studies
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=118133